Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Protara TherapeuticsPluristem TherapeuticsChampions OncologyX4 PharmaceuticalsAyala Pharmaceuticals
SymbolNASDAQ:TARANASDAQ:PSTINASDAQ:CSBRNASDAQ:XFORNASDAQ:AYLA
Price Information
Current Price$15.83$4.42$11.33$8.70$10.29
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.41.81.81.4
Analysis Score3.53.43.53.53.4
Community Score2.62.92.22.82.9
Dividend Score0.00.00.00.00.0
Ownership Score2.50.01.71.70.0
Earnings & Valuation Score0.60.61.91.30.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$47.67$9.75$16.00$18.60$24.20
% Upside from Price Target201.12% upside120.59% upside41.22% upside113.79% upside135.18% upside
Trade Information
Market Cap$190.78 million$138.41 million$154.39 million$155.59 million$135.52 million
Beta1.172.531.20.53N/A
Average Volume97,363714,37431,967111,41335,754
Sales & Book Value
Annual RevenueN/A$20,000.00$32.12 millionN/A$2.33 million
Price / SalesN/A6,967.914.72N/A58.16
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($21.67) per share$2.20 per share$0.45 per share$10.37 per shareN/A
Price / BookN/A2.0125.18N/A
Profitability
Net Income$-14,990,000.00$-29,150,000.00$-1,980,000.00$-52,810,000.00$-17,790,000.00
EPSN/AN/A($0.17)($4.63)N/A
Trailing P/E Ratio0.000.00N/AN/A0.00
Forward P/E RatioN/AN/A75.53N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-4.18%N/A-850.81%
Return on Equity (ROE)-45.45%-86.51%-29.93%-47.06%-625.24%
Return on Assets (ROA)-41.09%-68.23%-7.41%-35.89%-70.31%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.24%N/A
Current Ratio42.99%5.12%1.18%10.19%8.63%
Quick Ratio42.99%5.12%1.18%10.19%8.63%
Ownership Information
Institutional Ownership Percentage83.11%11.95%52.84%67.76%12.81%
Insider Ownership Percentage45.70%4.90%46.80%4.90%N/A
Miscellaneous
Employees271461436834
Shares Outstanding11.23 million31.53 million13.39 million17.38 million13.17 million
Next Earnings Date5/12/2021 (Estimated)5/10/2021 (Estimated)7/26/2021 (Estimated)5/6/2021 (Estimated)6/28/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Comparing Mesoblast (NASDAQ:MESO) and Ayala Pharmaceuticals (NASDAQ:AYLA)Comparing Mesoblast (NASDAQ:MESO) and Ayala Pharmaceuticals (NASDAQ:AYLA)
americanbankingnews.com - April 7 at 8:18 AM
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Receives Consensus Recommendation of "Buy" from BrokeragesAyala Pharmaceuticals, Inc. (NASDAQ:AYLA) Receives Consensus Recommendation of "Buy" from Brokerages
americanbankingnews.com - April 6 at 4:16 AM
Ayala Pharmaceuticals (NASDAQ:AYLA) Posts  Earnings Results, Misses Estimates By $0.15 EPSAyala Pharmaceuticals (NASDAQ:AYLA) Posts Earnings Results, Misses Estimates By $0.15 EPS
americanbankingnews.com - March 26 at 9:32 AM
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business UpdateAyala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 25 at 9:10 AM
Ayala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of SharesAyala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of Shares
finance.yahoo.com - February 24 at 11:15 PM
Ayala Pharmaceuticals raises $25M from private stock saleAyala Pharmaceuticals raises $25M from private stock sale
bizjournals.com - February 24 at 6:15 PM
Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16%Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16%
finance.yahoo.com - February 22 at 1:13 PM
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue TumorsAyala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
finance.yahoo.com - February 19 at 2:34 PM
Companies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In GrowthCompanies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In Growth
finance.yahoo.com - February 19 at 9:33 AM
ACIU & Alzheimers Vaccine, GNMK Rallies, ESSAs Prostate Cancer Drug On Track, MNPR On WatchACIU & Alzheimer's Vaccine, GNMK Rallies, ESSA's Prostate Cancer Drug On Track, MNPR On Watch
nasdaq.com - February 12 at 7:35 AM
NVAXs Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM TrialNVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
nasdaq.com - January 29 at 2:14 AM
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 ...Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 ...
apnews.com - January 28 at 11:10 AM
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast CancerAyala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
finance.yahoo.com - January 28 at 11:10 AM
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap ...Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap ...
apnews.com - January 13 at 8:55 PM
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor ConferenceAyala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
finance.yahoo.com - January 13 at 8:55 PM
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect ConferenceAyala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 5 at 11:57 AM
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in ...Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in ...
omaha.com - January 4 at 10:54 PM
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 StudyAyala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
finance.yahoo.com - January 4 at 12:53 PM
Ayala Pharmaceuticals IncAyala Pharmaceuticals Inc
reuters.com - December 16 at 7:44 AM
Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?
feedproxy.google.com - November 26 at 9:12 PM
Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64%Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64%
nasdaq.com - November 20 at 10:08 AM
Ayala Pharmaceuticals EPS misses by $0.03, beats on revenueAyala Pharmaceuticals EPS misses by $0.03, beats on revenue
seekingalpha.com - November 19 at 8:40 AM
Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business UpdateAyala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 17 at 9:49 AM
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesAyala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
finance.yahoo.com - November 5 at 9:48 AM
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for ...Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for ...
bakersfield.com - September 18 at 1:46 PM
DateCompanyBrokerageAction
3/21/2021Protara TherapeuticsOppenheimerReiterated Rating
10/19/2020Protara TherapeuticsCowenInitiated Coverage
7/29/2020Protara TherapeuticsGuggenheimInitiated Coverage
1/22/2020Protara TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
12/10/2020Pluristem TherapeuticsJefferies Financial GroupDowngrade
12/7/2020Pluristem TherapeuticsHC WainwrightReiterated Rating
10/9/2020Pluristem TherapeuticsDawson JamesReiterated Rating
5/15/2020Pluristem TherapeuticsMaxim GroupReiterated Rating
3/22/2021Champions OncologyRoth CapitalBoost Price Target
11/27/2019Champions OncologyBenchmarkInitiated Coverage
7/24/2019Champions OncologyJanney Montgomery ScottDowngrade
2/27/2019Champions OncologyNational SecuritiesInitiated Coverage
7/17/2018Champions OncologyCraig HallumInitiated Coverage
12/17/2020X4 PharmaceuticalsBrookline Capital ManagementInitiated Coverage
11/30/2020X4 PharmaceuticalsB. RileyReiterated Rating
11/9/2020X4 PharmaceuticalsCanaccord GenuityLower Price Target
3/26/2020X4 PharmaceuticalsCitigroupLower Price Target
6/7/2019X4 PharmaceuticalsStifel NicolausInitiated Coverage
1/25/2021Ayala PharmaceuticalsNoble FinancialReiterated Rating
8/13/2020Ayala PharmaceuticalsRaymond JamesReiterated Rating
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.